T2 Biosystems Announces Presentation on T2Sepsis Solution at AMP 2017
November 09 2017 - 8:00AM
T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the
development of innovative diagnostic products to improve patient
health, today announced a workshop presentation on the T2Sepsis
Solution™ during the Association for Molecular Pathology (AMP)
2017 Conference in Salt Lake City, UT on November 15. Attendees are
also invited to visit T2 Biosystems at Booth #211 throughout the
AMP Conference, where the Company will offer live demonstrations of
their diagnostic capabilities.
WORKSHOP PRESENTATION:TITLE:
T2Sepsis Solution: The Impact of Direct from Whole Blood
Diagnostics on the Management of Bloodstream
InfectionsPresenters: Chiagozie Ononye, M.D. of
Northwestern University’s Feinberg School of Medicine and Tom
Lowery, Ph.D. of T2 Biosystems.Overview: The
presenters will discuss the T2Sepsis Solution, a unique approach
that combines the standard of care for the management of sepsis
patients with T2 Biosystems’ products, including the T2Dx®
Instrument and T2Candida® Panel, and the T2Bacteria®
Panel, which is available for the research use only (RUO) in the US
and commercially available in Europe and other countries that
accept the CE Mark. Dr. Lowery will provide an overview of the
technology and discuss how the T2Sepsis Solution integrates with
the established hospital standard of care for sepsis patients. The
session will close with Dr. Ononye sharing her early experience
with the T2Bacteria RUO Panel when testing clinical specimens as
compared to paired blood culture results.Time:
9:00–9:50 a.m. MSTLocation: Calvin L. Rampton Salt
Palace Convention Center, Room 355D
About T2 Biosystems T2 Biosystems, an emerging
leader in the field of in vitro diagnostics, is dedicated to saving
lives and reducing the cost of healthcare by empowering clinicians
to effectively treat patients faster than ever before. T2
Biosystems is focused on addressing critical unmet needs in
healthcare starting with sepsis, one of the deadliest and most
expensive conditions in hospitals today. The T2Sepsis Solution is a
unique approach that combines the standard of care for the
management of sepsis patients with T2 Biosystems’ products,
including the T2Dx Instrument and T2Candida Panel, and the
T2Bacteria Panel, which is commercially available in Europe and
other countries that accept the CE Mark and available for research
use only in the U.S. Powered by the proprietary T2 Magnetic
Resonance technology, or T2MR®, the T2Sepsis Solution is proven to
deliver better patient care and greater cost savings. Hospital
customer experience has demonstrated faster time to effective
treatment, shortened ICU and hospital lengths of stay, reduced use
of unnecessary antifungals, and millions of dollars in savings. T2
Biosystems has an active pipeline of future sepsis products
including additional species and antibiotic resistance, as well as
tests for Lyme disease and hemostasis. For more information, please
visit www.t2biosystems.com.
Forward-Looking Statements This press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. All
statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking
statements, including, without limitation, statements regarding ,
product pipeline, anticipated product benefits, goals and strategic
priorities, product expansion or opportunities, growth expectations
or targets and FDA clearance, as well as statements that
include the words “expect,” “intend,” “plan,” “believe,” “project,”
“forecast,” “estimate,” “may,” “should,” “anticipate” and similar
statements of a future or forward-looking nature. These
forward-looking statements are based on management's current
expectations. These statements are neither promises nor guarantees,
but involve known and unknown risks, uncertainties and other
important factors that may cause actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, (i) any
inability to (a) realize anticipated benefits from commitments,
contracts or products; (b) successfully execute strategic
priorities; (c) bring products to market; (d) expand product usage
or adoption; (e) obtain customer testimonials; (f) accurately
predict growth assumptions; (g) realize anticipated revenues; (h)
incur expected levels of operating expenses; or (i) increase the
number of high-risk patients at customer facilities; (ii) failure
of early data to predict eventual outcomes; (iii) failure to
make or obtain anticipated FDA filings or clearances within
expected time frames or at all; or (iv) the factors discussed under
Item 1A. "Risk Factors" in the company's Annual Report on Form 10-K
for the year ended December 31, 2016, filed with the U.S.
Securities and Exchange Commission, or SEC, on March 15, 2017, and
other filings the company makes with the SEC from time to
time. These and other important factors could cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management's estimates as of
the date of this press release. While the company may elect to
update such forward-looking statements at some point in the future,
unless required by law, it disclaims any obligation to do so, even
if subsequent events cause its views to change. Thus, one should
not assume that the Company’s silence over time means that actual
events are bearing out as expressed or implied in such
forward-looking statements. These forward-looking statements should
not be relied upon as representing the company's views as of any
date subsequent to the date of this press release.
Company Contact:Darlene Deptula-Hicks, T2
BiosystemsSVP & Chief Financial
Officerddeptula@t2biosystems.com603-553-5803
Media Contact:Amy Phillips, Feinstein Kean
Healthcareamy.phillips@fkhealth.com412-327-9499
Investor Contact:Chris Brinzey, Westwicke
Partnerschris.brinzey@westwicke.com339-970-2843
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2024 to May 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From May 2023 to May 2024